Alkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -
Source: finanznachrichten.de